Prognostic Impact of Circumferential Resection Margin in Minimally Invasive Surgery for Locally Advanced Rectal Cancer: A Multicenter Prospective Study
Authors:
- Atsushi HamabeAHAtsushi Hamabe
- Masaaki ItoMIMasaaki Ito
- Shigeo TodaSTShigeo Toda
- Yusuke SuwaYSYusuke Suwa
- Suguru HasegawaSHSuguru Hasegawa
- Masanori KotakeMKMasanori Kotake
- Masafumi InomataMIMasafumi Inomata
- Kazuki UedaKUKazuki Ueda
- Atsushi OguraAOAtsushi Ogura
- Kiichi SugimotoKSKiichi Sugimoto
- Kei KimuraKKKei Kimura
- Koki OtsukaKOKoki Otsuka
Open Access
- 27 August 2026
- journal article
- Published by Wiley in Annals of Gastroenterological Surgery
Abstract
Aim: Circumferential resection margin (CRM) status is a well‐established prognostic factor in rectal cancer surgery; however, its long‐term oncological relevance has not been prospectively validated in Japan, where upfront surgery has long been widely used. This study assessed the prognostic impact of CRM in patients with locally advanced rectal cancer treated with minimally invasive surgery. Methods: The PRODUCT trial was a multicenter, prospective, observational study conducted at 18 institutions in Japan. Patients aged ≥ 20 years with clinical stage II or III rectal adenocarcinoma located within 12 cm from the anal verge and scheduled for laparoscopic or robotic surgery were enrolled. CRM positivity was defined as a margin of ≤ 1 mm. Long‐term outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards regression models. Results: Among 303 eligible patients, CRM positivity was observed in 26 (8.6%). The 3‐year recurrence‐free survival (RFS) rate was significantly lower in the CRM‐positive group than in the CRM‐negative group (61.5% vs. 82.3%; log‐rank p = 0.003). CRM positivity was independently associated with worse RFS (hazard ratio, 2.35; 95% confidence interval, 1.17–4.71; p = 0.016). In patients with pT3–T4 tumors, recurrence rates were significantly higher in CRM‐positive cases than in CRM‐negative cases (47.6% vs. 21.2%; p = 0.013). CRM status was not significantly associated with overall survival or cumulative incidence of local recurrence ( p = 0.057 and p = 0.706, respectively). Conclusions: CRM positivity is an adverse prognostic factor in Japanese patients with locally advanced rectal cancer undergoing MIS, underscoring the clinical importance of standardized CRM assessment. Trial Registration: Clinical Trials Registry, Identification Number: UMIN00034365Keywords
This publication has 27 references indexed in Scilit:
- Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of lifeCancer Treatment Reviews, 2025
- Robotic vs Laparoscopic Surgery for Middle and Low Rectal CancerJAMA, 2025
- Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant TherapyJAMA Network Open, 2024
- Japanese multicenter prospective study investigating laparoscopic surgery for locally advanced rectal cancer with evaluation of CRM and TME quality (PRODUCT trial)Annals of Gastroenterological Surgery, 2022
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2019
- Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal CancerJAMA, 2017
- Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic OutcomesJAMA, 2015
- Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical TrialJAMA, 2015
- The prediction of local recurrence in rectal adenocarcinoma by histopathological examinationInternational Journal of Colorectal Disease, 1988